Insmed (NASDAQ:INSM) COO Roger Adsett Sells 2,059 Shares

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 2,059 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $174.17, for a total value of $358,616.03. Following the transaction, the chief operating officer directly owned 107,601 shares in the company, valued at $18,740,866.17. This trade represents a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Roger Adsett also recently made the following trade(s):

• On Wednesday, January 7th, Roger Adsett sold 802 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $140,406.14.
• On Tuesday, January 6th, Roger Adsett sold 1,429 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total transaction of $247,688.57.

Insmed Price Performance

INSM opened at $170.27 on Friday. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $212.75. The firm has a market cap of $36.31 billion, a price-to-earnings ratio of -27.51 and a beta of 1.08. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. The company has a fifty day simple moving average of $190.31 and a 200 day simple moving average of $151.37.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The business had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. During the same quarter in the prior year, the business earned ($1.27) earnings per share. The firm’s revenue was up 52.4% on a year-over-year basis. Equities research analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Company update: Insmed reported strong unaudited revenues tied to its commercial launches—BRINSUPRI posted roughly $144.6M in total revenue in its first full quarter and ~$172.7M for full-year 2025; ARIKAYCE generated ~ $433.8M for 2025, exceeding the top end of prior guidance. Management provided 2026 ARIKAYCE guidance of $450M–$470M, signaling continued commercial momentum. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: Pipeline timing: Management updated clinical timelines — ENCORE (ARIKAYCE Phase 3) topline now expected March/April 2026 and CEDAR (brensocatib Phase 2b in HS) topline anticipated in Q2 2026. These upcoming readouts are material catalysts but the shifted timing may compress near-term volatility. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: New Phase‑3 starts: Insmed initiated the PALM‑ILD Phase 3 for TPIP in PH‑ILD in Q4 2025 and plans further Phase 3 studies in PAH, PPF and IPF in 2026 — a positive R&D cadence but one that increases near-term spend and execution risk. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: Media attention: Jim Cramer flagged Insmed as “worth keeping an eye on,” which can boost retail interest and liquidity but is not a fundamental endorsement. Jim Cramer on Insmed
• Negative Sentiment: Insider selling: Multiple executives (CEO, CFO, COO and others) have recently sold shares across Jan. 6–8, and a report flagged approximately $15.29M in insider sales—activity that can signal near-term profit-taking or create negative perception among investors. Insider Selling: Insmed Insider Sells $15,293,208.00 in Stock
• Negative Sentiment: Investor litigation alert: Pomerantz LLP launched an investor investigation related to Insmed, which introduces potential legal and reputational risk and could weigh on sentiment until clarified. Pomerantz Investigates Claims On Behalf of Investors of Insmed

Institutional Trading of Insmed

A number of large investors have recently modified their holdings of INSM. CIBC Private Wealth Group LLC boosted its stake in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares during the period. Kingsview Wealth Management LLC raised its holdings in shares of Insmed by 2.7% during the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 60 shares during the last quarter. Choreo LLC grew its holdings in Insmed by 2.9% in the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 65 shares in the last quarter. Spire Wealth Management increased its position in Insmed by 11.5% in the 3rd quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 80 shares during the period. Finally, MassMutual Private Wealth & Trust FSB raised its stake in Insmed by 59.6% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 81 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on INSM shares. The Goldman Sachs Group boosted their target price on shares of Insmed from $225.00 to $258.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Truist Financial started coverage on Insmed in a report on Friday, December 19th. They issued a “buy” rating and a $202.00 price target for the company. Wolfe Research set a $167.00 price objective on Insmed and gave the stock an “outperform” rating in a research note on Thursday, December 18th. HC Wainwright lowered their target price on shares of Insmed from $240.00 to $230.00 and set a “buy” rating for the company in a research note on Thursday, December 18th. Finally, Wedbush set a $203.00 price target on shares of Insmed in a research report on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $205.64.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.